Uzay GÖRMÜŞ, İlkkan DÜNDER, Nilgün GÜDÜCÜ, Özge Başak KAYAN, Zehra Neşe KAVAK

The relationship between affective disorders and hormonal and metabolic parameters in women with polycystic ovary syndrome

Amaç: Polikistik over sendromlu (PKOS) hastalarda afektif bozukluklar ile hormonal ve biyokimyasal paramet- reler arasındaki ilişkiyi anlamak. Yöntemler: PKOS tanısı almış 15 hasta, yaş ve vücutkitle endeksi benzer olan kontrol grubuyla (n=19) karşı- laştırıldı. Beck Depresyon Ölçeği ve Durumluk-SürekliAnksiyete Ölçeği kullanılarak anksiyete ve depresyonsemptomları sorgulandı. Bulgular: Polikistik over sendromlu hastaların depres- yon ve anksiyete skorları serbest testosterone seviyeleri ile korele idi. Anksiyete skorları HDL ve kardiyovaskülerhastalıklar için bağımsız bir risk faktörü olarak kabul edi- len lipoprotein-a ile koreleydi. Kontrol grubunda anksiyeteskorları interlökin 1beta ile koreleydi. Sonuç: Polikistik over sendromlu hastalarda androjenler ve afektif bozukluklar arasında bağlantı vardır. Lipopro- tein-a ve anksiyete skorları arasındaki korelasyon afek- tif bozukluklar ve kardiyovasküler hastalıklar arasındakibağ olabilir. Polikistik over sendromlu kadınlarda afektif bozuklukların patofizylojisinde farklı bir mekanizma rol oynayabilir.

Polikistik over sendromlu kadınlarda afektif bozukluklar ile hormonal ve metabolik parametreler arasındaki ilişki

Objective: To understand the relationship among affec-tive disorders and hormonal and biochemical parametersin women with polycystic ovary syndrome (PCOS).Methods: Women with PCOS (n=15) were compared tobody mass index and age matched control group (n=19).Beck Depression Inventory and Stait Trait Anxiety Inven-tory were used to assess the presence of depression andanxiety symptoms.Results: Depression and anxiety scores of women withPCOS correlated with free testosterone levels. Their anxi-ety scores correlated with HDL and lipoprotein-a (Lp-a),an independent marker for increased cardiovascular dis-ease. In the control group anxiety score correlated withinterleukin-1β.Conclusion: There was a relationship between increasedandrogens and affective disorders in women with PCOS.The correlation between Lp-a and anxiety scores maybe the link between affective disorders and cardiovas-cular diseases. A different mechanism may play role inthe pathophysiology of affective disorders in women withPCOS.

PDF

___

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
2. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-294.
3. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
4. Raikkonen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation Definitions. Diabetes Care 2007;30:872-877.
5. Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Pschiatry 2007;62:1251-1257.
6. Cinar N, Kizilarslanoğlu MC, Harmanci, et al. Depression, anxiety and polycystic ovary syndrome. Hum Reprod 2011;26:3339-3345.
7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
8. Güngör O, Erden G, Bal C, et al. The comparison of free androgen index and serum free testosterone levels in women with hirsutism or polycystic ovary syndrome. J Clin Exp Invest 2011;2:152-156.
9. Benson S, Janssen OE, Hahn S, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain, Behavior, and Immunity 2008;22:177-184.
10. Keegan A, Liao LM, Boyle M. ‘Hirsutism’: a psycho- logical analysis. J Health Psychol 2003;8:327-345. 11. Mansson M, Holte J, Landin-Wilhemsen K, et al. Women with polycystic ovary syndrome are often de- pressed and anxious- a case control study. Psycho- neuroendocrinology 2008;33:1132-1138.
12. McCook JG, Reame NE, Thatcher SS. Health-re- lated quality of life issues in women with polycystic ovary syndrome J Obstet Gynecol Neonatal Nurs 2005;34:12-20.
13. Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003;74:299- 304
14. Adali E, Yildizhan R, Kurdoglu M, et al. The relation- ship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res 2008;36:1188-1196.
15. Hollinrake E, Abreu A, Maifeld M, et al. Increased risk of depressive symptoms in women with polycystic ovary syndrome. Fertil Steril 2007;87:1369-1372.
16. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovary syndrome to healthy controls. Psychosom Med 2004;66:356-362.
17. Jedel E, Gustafson D, Waern M, et al. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology 2011;36:1470-1479.
18. Dokras A, Clifton S, Futterweit W, et al. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta- analysis. Obstet Gynecol 2011;117:145-152.
19. Weber B, Lewicka S, Deuschle et al. Testosterone, androstenedione and dihydrotestosterone concentra- tions are elevated in female patients with major de- pression. Psychoneuroendocrinology 2000;25:765- 771.
20. Morsink LFJ, Vogelzangs N, Nicklas BJ, et al. Health ABCs. Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study. Psycho- neuroendocrinology 2007;32:874-883.
21. Miller KK, Perlis RH, Papakostas GI, et al. Low dose transdermal testosterone augmentation therapy im- proves depression severity in women. CNS Spectr 2009;14:688-694
22. Moghetti P, Castello R, Negri C, et al. Metformin ef- fects on clinical features, and endocrine and meta- bolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo con- trolled 6 month trial, followed by open, long-term clini- cal evaluation. J Clin Endocrinol Metab 2000;85:139- 146.
23. Sverissidottir YB, Mogren T, Kataoka J, et al. Is poly- cystic ovary syndrome associated with high sympa- thetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 2008;294:576-581.
24. Feng Y, Shao R, Weijdegard B, et al. Effects of andro- gen and leptin on behavioral and cellular responses in female rats. Hormones and Behavior 2011;60:427- 438.
25. Benson S, Arck PC, Tan S, et al. Disturbed stress re- sponses in women with polycystic ovary syndrome. Psychoneuroendocrinology 2009;34:727-735.
26. Maes M, Scharpe S, Meltzer HY, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993;49:11-27.
27. Piletz JE, Halaris A, Igbal O, et al. Pro-inflammatory markers in depression: Treatment with venlafaxine. World J Biol Psychiatry 2009;10:313-323.
28. Livadas S, Chaskou S, Kandaraki AA, et al. Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. Clin Endo- crinol 2011;75:698-703.
29. Hahn S, Benson S, Elsenbruch S, et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress, and sexuality. Hum Reprod 2006;2:1925-1934.
30. Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2010;16:347-363 .
31. Berneis K, Rizzo M, Hersberger M, et al. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin Pract. 2009;63:56-62.